Showing results (331-340 of 355) with videos related to

Sort By:
Pageof 36
ACR Open Rheumatology|March 7, 2023
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 StudiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
The Journal of Biological Chemistry|November 7, 2013
Transient receptor potential channel 6 (TRPC6) protects podocytes during complement-mediated glomerular diseaseAndreas D Kistler, Geetika Singh, Mehmet M Altintas, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2021
Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Cancer Immunology, Immunotherapy : CII|June 28, 2019
Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV modelEiichi Ishida, Jina Lee, Jean S Campbell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 11, 2026
Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE StudyAlexis Ogdie, Joseph F Merola, Philip J Mease, et al.
Rheumatology and Therapy|November 14, 2025
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor InhibitorsPhilip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
Advances in Therapy|November 21, 2025
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A InhibitorsPhilip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
BMC Rheumatology|May 21, 2024
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled studyAlexis Ogdie, Joseph F Merola, Philip J Mease, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Clinical and molecular characterization of patients with cancer of unknown primary in the modern eraA M Varghese, A Arora, M Capanu, et al.
Trials|March 19, 2025
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trialAlexis Ogdie, Soumya M Reddy, Sarah H Gillespie, et al.
Pageof 36